Racepinephrine Inhalation Solution Recalled for Improper Storage Conditions
Mckesson Medical-Surgical is recalling S2 Racepinephrine Inhalation Solution due to storage that deviated from label specifications. This Class II recall affects 23 cartons distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses, hospitalizations, or injuries. The hazard is a manufacturing compliance deviation (improper storage conditions), not a confirmed contamination or ingredient defect, making it a precautionary recall.
Plain-English summary
S2 Racepinephrine Hydrochloride Inhalation Solution, a bronchodilator medication for oral inhalation, is being recalled by Mckesson Medical-Surgical Inc. The product is a sterile inhalation solution in 0.5 mL unit-of-use vials, supplied in cartons of 30.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations: products were stored outside the conditions specified on the drug label. This storage deviation may affect product quality.
The affected product was distributed nationwide in the United States. The recall involves 23 cartons.
Patients currently using this product should consult their healthcare provider for guidance. Patients with questions about this recall should contact their pharmacy or healthcare provider.
The recalled product
- Product
- S2 (RACEPINEPHRINE HYDROCHLORIDE)
- Brand
- S2
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Hazard
- improper-storage
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · S2
- ModerateDrug Recall: S2 Racepinephrine Inhalation Solution Short Fill
FDA (Drugs) · 2023-02-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27